【摘要】：急性髓細(xì)胞白血病(Acute Myeloid Leukemia,AML)是最常見的成人血液系統(tǒng)惡性腫瘤,其發(fā)病機(jī)制極為復(fù)雜,大多數(shù)AML的發(fā)生為自身遺傳因素與外界環(huán)境因素共同作用的結(jié)果,且具體發(fā)病過程涉及多個致病因素在多個步驟的相互作用。有關(guān)AML發(fā)病機(jī)制的學(xué)說眾多,“二次打擊”學(xué)說具有代表性,該學(xué)說認(rèn)為AML的發(fā)生一般來說至少有二個階段:即各種原因所致的單個細(xì)胞內(nèi)基因的決定性突變,激活某種信號通路,導(dǎo)致了克隆性異常造血細(xì)胞生成和強(qiáng)勢增殖,凋亡受阻;進(jìn)一步遺傳學(xué)改變再涉及到某些轉(zhuǎn)錄因子,導(dǎo)致克隆性增殖的異常造血細(xì)胞分化阻滯或紊亂,從而引起白血病�，F(xiàn)代免疫學(xué)觀點認(rèn)為,各種免疫細(xì)胞及其相關(guān)免疫分子表達(dá)和功能的動態(tài)平衡是機(jī)體維持各項免疫功能的重要保障。故大多數(shù)疾病的發(fā)生除了自身特殊的發(fā)病機(jī)理外,幾乎均涉及到機(jī)體免疫平衡紊亂而導(dǎo)致的功能缺陷。我們前期的研究提示免疫功能缺陷同樣是AML發(fā)生發(fā)展的重要原因。CD4+CD25+調(diào)節(jié)性T細(xì)胞(CD4+CD25+Regulatory T Cells,Tregs)是一群免疫負(fù)調(diào)控細(xì)胞,具有下調(diào)免疫應(yīng)答的免疫抑制功能,可通過細(xì)胞-細(xì)胞接觸或分泌抑制性細(xì)胞因子來抑制免疫效應(yīng)細(xì)胞的活性。在免疫調(diào)節(jié)、維持外周免疫耐受和防止自身免疫性疾病等方面發(fā)揮著重要的作用。多項研究表明,Tregs是誘導(dǎo)保護(hù)AML細(xì)胞逃逸機(jī)體抗腫瘤免疫應(yīng)答的關(guān)鍵因素之一。IL-35是近年來新發(fā)現(xiàn)的一種細(xì)胞因子,由IL-12α亞基p35和IL-27β亞基EB病毒誘導(dǎo)的基因3(Epstein-Barr Virus Induced Gene 3,EBI3)以異二聚體的形式組成。研究發(fā)現(xiàn)小鼠的IL-35僅特異性、組成性地來源于Tregs,但在人體內(nèi),IL-35的來源和表達(dá)尚不完全明確。目前普遍認(rèn)為IL-35是一種新的抑制性細(xì)胞因子,它可以顯著促進(jìn)Tregs的增殖,抑制CD4+CD25-效應(yīng)性T細(xì)胞(CD4+CD25-Effector T Cells,Teffs)增殖及其分泌的細(xì)胞因子,此外,它還可以誘導(dǎo)初始T細(xì)胞分化成一種被稱為“i Tr35”(IL-35 Induced Regulatory T Cells)的Tregs新亞群,從而級聯(lián)放大Tregs的免疫調(diào)節(jié)作用。鑒于IL-35在Tregs分化發(fā)育和功能活性中的關(guān)鍵作用,我們推測IL-35可以促進(jìn)AML患者體內(nèi)Tregs積累和功能增強(qiáng),最終導(dǎo)致機(jī)體內(nèi)Tregs和Teffs之間的平衡向抑制性偏倚,有利于AML細(xì)胞逃逸機(jī)體的抗腫瘤免疫應(yīng)答。此外,衰老基因SENEX可能通過誘導(dǎo)應(yīng)力性衰老(Stress Induced Premature Senescence,SIPS)的發(fā)生而保護(hù)Tregs,參與AML的發(fā)生發(fā)展。我們前期收集了AML患者的外周血標(biāo)本,對IL-35在AML中的表達(dá)及誘導(dǎo)AML細(xì)胞免疫逃逸的作用和機(jī)制進(jìn)行了初步的研究,結(jié)果顯示,AML患者體內(nèi)IL-35的表達(dá)升高且與疾病的發(fā)生發(fā)展密切相關(guān),IL-35可以促進(jìn)Tregs和i Tr35的表達(dá)和功能、抑制Teffs的功能,從而介導(dǎo)AML細(xì)胞的免疫逃逸。本課題進(jìn)一步研究抑制性細(xì)胞因子IL-35在AML患者骨髓中的表達(dá)及其對AML細(xì)胞的直接作用,結(jié)合前期相關(guān)研究及本次研究結(jié)果探討IL-35對AML免疫功能的影響及其機(jī)制。本研究共選取20例成人初診AML患者作為研究對象,并進(jìn)行為期2年的追蹤隨訪,其中17人在治療后獲得了完全緩解,5人其后又復(fù)發(fā),同時按照年齡、性別相匹配的原則,選取了7例缺鐵性貧血患者作為對照組,然后對IL-35在AML患者骨髓中的表達(dá)及其對AML細(xì)胞的作用進(jìn)行了分析。具體實驗方法和實驗結(jié)果如下:(1)實驗采用多種方法(PCR、ELISA、FCM、IHC)檢測AML初診組和對照組骨髓標(biāo)本中IL-35的表達(dá)情況,結(jié)果表明,與對照組相比,初診AML患者骨髓中IL-35的表達(dá)顯著升高,提示,IL-35與AML的發(fā)生有關(guān)。(2)實驗采用ELISA的方法檢測AML進(jìn)展的不同階段IL-35蛋白的表達(dá),結(jié)果顯示,在初診AML患者骨髓中IL-35蛋白的表達(dá)顯著增高,在獲得完全緩解后其表達(dá)降低,而復(fù)發(fā)時又再度升高。提示,IL-35與AML的發(fā)展密切相關(guān)。(3)實驗采用FCM的方法檢測AML進(jìn)展的不同階段Tregs的表達(dá)情況,結(jié)果表明,初診AML患者骨髓中Tregs的比例升高,獲得完全緩解后其比例降低,而復(fù)發(fā)時又再度升高,且Person相關(guān)性分析表明,初診AML患者骨髓中IL-35的表達(dá)水平與其各自的Tregs和叉頭樣轉(zhuǎn)錄因子p3(Forkhead Box p3,Foxp3)表達(dá)水平顯著正相關(guān),初步提示,在AML中Tregs可能是IL-35的來源之一,或者其他來源的IL-35可以顯著促進(jìn)AML患者體內(nèi)Tregs的表達(dá)。(4)實驗對AML細(xì)胞株進(jìn)行培養(yǎng)和干預(yù),通過對IL-35刺激的AML細(xì)胞株增殖和凋亡情況進(jìn)行分析發(fā)現(xiàn),IL-35顯著上調(diào)AML細(xì)胞株中IL-35R的表達(dá),同時與PBS對照組相比IL-35還明顯促進(jìn)AML細(xì)胞株的增殖,進(jìn)一步研究發(fā)現(xiàn),IL-35預(yù)刺激的AML細(xì)胞株能顯著抵抗阿糖胞苷(Ara-C)誘導(dǎo)的凋亡。(5)實驗對FCM分選的患者骨髓中AML原始細(xì)胞進(jìn)行培養(yǎng)和干預(yù),通過對IL-35刺激的AML細(xì)胞增殖情況進(jìn)行分析,同樣發(fā)現(xiàn)IL-35顯著上調(diào)AML細(xì)胞中IL-35R的表達(dá),同時顯著促進(jìn)AML細(xì)胞的增殖,而凋亡實驗也發(fā)現(xiàn)IL-35預(yù)刺激的AML細(xì)胞能顯著抵抗阿糖胞苷(Ara-C)誘導(dǎo)的凋亡。提示,IL-35可以通過與其受體結(jié)合作用于AML細(xì)胞,并顯著促進(jìn)AML細(xì)胞的增殖、抑制AML細(xì)胞的凋亡。(6)實驗采用Real-time PCR的方法檢測AML進(jìn)展不同階段SENEX基因的表達(dá)情況,結(jié)果顯示,在初診AML患者骨髓中SENEX基因的表達(dá)顯著增高,獲得完全緩解后其表達(dá)降低,復(fù)發(fā)時又再度升高,提示,SENEX基因與AML的發(fā)生發(fā)展密切相關(guān)。綜上,AML是一種發(fā)病機(jī)制與免疫因素密切相關(guān)的常見血液腫瘤,一般認(rèn)為抑制性細(xì)胞及細(xì)胞因子在AML患者體內(nèi)的積聚,使得免疫系統(tǒng)的平衡被打破免疫功能受到抑制,從而有利于AML細(xì)胞逃逸機(jī)體的抗腫瘤免疫應(yīng)答,最終導(dǎo)致AML的發(fā)生發(fā)展。本研究發(fā)現(xiàn),抑制性細(xì)胞因子IL-35顯著高表達(dá)于AML,且可通過促進(jìn)Tregs、抑制Teffs的表達(dá)和功能以及直接促進(jìn)AML細(xì)胞增殖和抑制AML細(xì)胞的凋亡來參與AML的發(fā)生發(fā)展。同時,衰老基因SENEX誘導(dǎo)的SIPS具有抗凋亡和免疫抑制效應(yīng),故推測衰老基因SENEX是促進(jìn)AML免疫逃逸的機(jī)制之一。
[Abstract]:Acute Myeloid Leukemia (AML) is the most common malignant tumor of the adult blood system. Its pathogenesis is very complex. Most of the occurrence of AML is the result of the interaction of its own genetic factors and the external environmental factors, and the specific pathogenesis involves the interaction of multiple pathogenic factors in multiple steps. The related AML hair is related to the pathogenesis of AML. The theory of the disease mechanism is numerous, and the theory of "two times" is representative. The theory holds that the occurrence of AML is generally at least two stages: the decisive mutation of the gene in a single cell caused by various reasons, activating a certain signal pathway, resulting in the formation of cloned abnormal hematopoietic cells and strong proliferation, and the inhibition of apoptosis; further remains. In modern immunological view, the dynamic balance between the expression and function of various immune cells and their related immune molecules is an important guarantee for the body to maintain the various immune functions. In addition to its own special pathogenesis, it almost all involves the functional defects caused by the body's immune balance disorder. Our previous study suggests that immune deficiency is also an important cause of the development of AML (CD4+CD25+Regulatory T Cells, Tregs), a group of immune negative regulatory cells, with down regulation. The immunosuppressive function of the immune response can inhibit the activity of immune effector cells by cell cell contact or secretion of inhibitory cytokines. It plays an important role in immune regulation, maintaining peripheral immune tolerance and preventing autoimmune diseases. A number of studies have shown that Tregs is the induction of protection against swelling in AML cells. One of the key factors of the tumor immune response.IL-35 is a newly discovered cytokine in recent years. The gene 3 (Epstein-Barr Virus Induced Gene 3, EBI3), induced by the IL-12 alpha subunit p35 and IL-27 beta subunit EB virus, is composed of a hetero two polymer. The origin and expression of -35 are still not completely clear. It is widely believed that IL-35 is a new inhibitory cytokine that can significantly promote the proliferation of Tregs, inhibit the proliferation and secretion of CD4+CD25- effector T cells (CD4+CD25-Effector T Cells, Teffs), and also induce the differentiation of initial T cells into one kind known as "" The Tregs new subgroup of I Tr35 "(IL-35 Induced Regulatory T Cells) amplifies the immune regulation of Tregs in cascade. In view of the key role of IL-35 in Tregs differentiation and functional activity, we speculate that IL-35 can promote accumulation and function enhancement in the patient's body and ultimately lead to a balance between the body and the body. In addition, the aging gene SENEX may protect Tregs and participate in the occurrence and development of AML by inducing the occurrence of Stress Induced Premature Senescence (SIPS), and we have collected the peripheral blood specimens of AML patients, and the expression and induction of IL-35 in AML, by inducing the occurrence of Stress Induced Premature Senescence (SIPS). The effect and mechanism of AML cell immune escape were preliminarily studied. The results showed that the expression of IL-35 in AML patients was elevated and closely related to the development of the disease. IL-35 could promote the expression and function of Tregs and I Tr35, inhibit the function of Teffs and mediate the immune escape of AML fine cells. This subject further studies the inhibitory fine. The expression of cytokine IL-35 in the bone marrow of patients with AML and its direct effect on AML cells, combined with the previous study and the results of this study to explore the effect and mechanism of IL-35 on the immune function of AML. A total of 20 cases of adult first diagnosed AML patients were selected and followed up for a period of 2 years, of which 17 of them were obtained after treatment. With complete remission, 5 people then relapsed, and 7 cases of iron deficiency anemia were selected as the control group according to the age and sex matching principle. Then the expression of IL-35 in the bone marrow of AML patients and the effect on AML cells were analyzed. The specific experimental methods and the results were as follows: (1) the experiment adopted a variety of methods (PCR, ELISA, F). CM, IHC) detected the expression of IL-35 in the bone marrow specimens of the AML first diagnosis group and the control group. The results showed that the expression of IL-35 in the bone marrow of the first diagnosed AML patients was significantly higher than that of the control group, suggesting that IL-35 was related to the occurrence of AML. (2) the experiment used ELISA method to detect the expression of IL-35 protein in the different stages of AML progress. The results showed that the first diagnosis of AML patients was in the first diagnosis. The expression of IL-35 protein in the bone marrow was significantly increased, and the expression decreased after complete remission, while the recurrence increased again. It suggested that the development of IL-35 was closely related to the development of AML. (3) the expression of Tregs in different stages of AML was detected by FCM. The results showed that the proportion of Tregs in the bone marrow of first diagnosed AML patients was increased, and the results were finished. After full remission, the ratio of IL-35 was increased again, and the Person correlation analysis showed that the expression level of IL-35 in the bone marrow of first diagnosed AML patients was significantly correlated with their respective Tregs and P3 (Forkhead Box P3, Foxp3) expression level. It was suggested that Tregs may be one of the sources of IL-35, or other sources in AML. The source of IL-35 can significantly promote the expression of Tregs in AML patients. (4) the experiment on AML cell line culture and intervention, through the analysis of the proliferation and apoptosis of IL-35 stimulated AML cell lines, IL-35 significantly up-regulated the expression of IL-35R in AML cell lines, while IL-35 also significantly promoted the proliferation of AML cell lines compared with the PBS control group. Further studies have found that the IL-35 pre stimulated AML cell line can significantly resist the apoptosis induced by cytarabine (Ara-C). (5) the experiment on the AML primordial cells in the bone marrow of the FCM separation patients was cultured and intervened, and the proliferation of AML cells stimulated by IL-35 was analyzed. The same discovery that IL-35 significantly up-regulated the expression of IL-35R in AML cells. The proliferation of AML cells was significantly promoted, and the apoptosis experiment also found that IL-35 prestimulated AML cells could significantly resist the apoptosis induced by cytarabine (Ara-C). It is suggested that IL-35 can combine with its receptor in AML cells, promote the proliferation of AML cells and inhibit the apoptosis of AML cells. (6) the experiment used Real-time PCR method to detect AML. The expression of SENEX gene in different stages showed that the expression of SENEX gene in the bone marrow of first diagnosed AML patients was significantly higher, and the expression decreased after complete remission, and the recurrence was increased again. It suggested that the SENEX gene was closely related to the development of AML. To sum up, AML is a common pathogenesis closely related to the immune factors. The accumulation of inhibitory cells and cytokines in AML patients is generally believed to make the balance of the immune system be suppressed by the break of the immune function, which is beneficial to the anti tumor immune response of the AML cells to escape the body and ultimately lead to the development of AML. This study found that the inhibitory cytokine IL-35 is highly expressed in AML. And it can participate in the development of AML by promoting Tregs, inhibiting the expression and function of Teffs and promoting the proliferation of AML cells and inhibiting the apoptosis of AML cells. At the same time, the senescence gene SENEX induced SIPS has the anti apoptosis and immunosuppressive effect. Therefore, the senescence gene SENEX is one of the mechanisms to promote the escape of the AML immune system.
【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2016
【分類號】：R733.71

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 羅曉丹;劉啟發(fā);;細(xì)胞因子與慢性移植物抗宿主病關(guān)系研究[J];中國實用內(nèi)科雜志;2007年03期

2 李曉紅;盛光耀;;兒童特發(fā)性血小板減少性紫癜多項細(xì)胞因子測定價值研究[J];現(xiàn)代預(yù)防醫(yī)學(xué);2011年15期

3 曹雪濤;第二屆國際細(xì)胞因子會議評介[J];中國免疫學(xué)雜志;1990年03期

4 曹雪濤,葉天星,杜平;細(xì)胞因子和細(xì)胞因子網(wǎng)絡(luò)的基礎(chǔ)研究進(jìn)展[J];國外醫(yī)學(xué)(免疫學(xué)分冊);1990年05期

5 曹雪濤,葉天星,杜平;細(xì)胞因子和細(xì)胞因子網(wǎng)絡(luò)的臨床研究進(jìn)展[J];國外醫(yī)學(xué)(免疫學(xué)分冊);1990年05期

6 史久華;細(xì)胞因子與疾病[J];國外醫(yī)學(xué).預(yù)防.診斷.治療用生物制品分冊;1993年05期

7 劉衛(wèi)京,呂秋軍;細(xì)胞因子小分子模擬物研究進(jìn)展[J];藥學(xué)學(xué)報;2000年11期

8 孟憲鈞;外科感染和細(xì)胞因子[J];中國實用外科雜志;2000年12期

9 ;《細(xì)胞因子研究方法學(xué)》工具書出版[J];中華微生物學(xué)和免疫學(xué)雜志;2000年03期

10 趙武述;細(xì)胞因子研究的臨床意義及展望[J];中華檢驗醫(yī)學(xué)雜志;2000年04期

相關(guān)會議論文 前10條

1 王志國;陳波;肖亮;張顥;展昭民;張伯龍;馬軍;;細(xì)胞因子在急性移植物抗宿主病中的臨床研究[A];第12屆全國實驗血液學(xué)會議論文摘要[C];2009年

2 竇永喜;景志忠;候俊琳;駱學(xué)農(nóng);才學(xué)鵬;;細(xì)胞因子及其應(yīng)用研究進(jìn)展[A];中國畜牧獸醫(yī)學(xué)會家畜寄生蟲學(xué)分會第五次代表大會暨第八次學(xué)術(shù)研討會論文集[C];2004年

3 竇永喜;景志忠;候俊琳;駱學(xué)農(nóng);才學(xué)鵬;;細(xì)胞因子及其應(yīng)用研究進(jìn)展[A];中國畜牧獸醫(yī)學(xué)會家畜寄生蟲學(xué)分會第五次代表大會暨第八次學(xué)術(shù)研討會論文集[C];2004年

4 竇永喜;景志忠;候俊琳;駱學(xué)農(nóng);才學(xué)鵬;;細(xì)胞因子及其應(yīng)用研究進(jìn)展[A];中國畜牧獸醫(yī)學(xué)會家畜寄生蟲學(xué)分會第五次代表大會暨第八次學(xué)術(shù)研討會論文集[C];2004年

5 張鳳蘊(yùn);呂雪瑩;于偉玲;王麗群;王琳;李殿俊;;實驗性變態(tài)反應(yīng)性腦脊髓炎幾種細(xì)胞因子的檢測[A];慶祝黑龍江省免疫學(xué)會成立十周年（1993—2003）論文集[C];2003年

6 鄒崢;張淑華;柯江維;;小兒幼年類風(fēng)濕關(guān)節(jié)炎細(xì)胞因子產(chǎn)生及干預(yù)的研究[A];全國自身免疫性疾病專題研討會暨第十一次全國風(fēng)濕病學(xué)學(xué)術(shù)年會論文匯編[C];2006年

7 鄒崢;張淑華;柯江維;;小兒幼年類風(fēng)濕關(guān)節(jié)炎細(xì)胞因子產(chǎn)生及干預(yù)的研究[A];全國自身免疫性疾病專題研討會暨第十一次全國風(fēng)濕病學(xué)學(xué)術(shù)年會論文匯編[C];2006年

8 鄒崢;張淑華;柯江維;華學(xué)明;劉小惠;;小兒幼年特發(fā)性關(guān)節(jié)細(xì)胞因子產(chǎn)生及干預(yù)的研究[A];中華醫(yī)學(xué)會第十四次全國兒科學(xué)術(shù)會議論文匯編[C];2006年

9 萬遂如;;細(xì)胞因子與細(xì)胞因子療法[A];中國畜牧獸醫(yī)學(xué)會動物傳染病學(xué)分會第十二次學(xué)術(shù)研討會論文集[C];2007年

10 劉占國;袁小彭;羅宇維;何懿;孫爾維;;通過細(xì)胞因子譜評估免疫抑制劑對人免疫狀態(tài)的作用[A];全國臨床免疫檢驗研討會暨第六屆全國臨床免疫學(xué)術(shù)會議論文匯編[C];2009年

相關(guān)重要報紙文章 前10條

1 仇逸;口服細(xì)胞因子治療腫瘤將獲突破[N];醫(yī)藥經(jīng)濟(jì)報;2009年

2 通訊員 何育萍 記者 王玉華;我省細(xì)胞因子研究獲重大突破[N];湖北日報;2001年

3 徐州市第一人民醫(yī)院血液科 張魯勤;白介素18等細(xì)胞因子在非惡性血液病中的作用及臨床研究[N];徐州日報;2005年

4 安徽醫(yī)科大學(xué)臨床藥理研究所徐叔云 魏偉 王華 吳成義 李常玉;細(xì)胞因子是柄雙刃劍[N];中國醫(yī)藥報;2003年

5 本報特約通訊員　吳志軍;向一個個“第一”沖擊[N];解放軍報;2002年

6 王振坤;人體的血液防線之一[N];家庭醫(yī)生報;2007年

7 ;獨辟蹊徑 追根溯源[N];中國醫(yī)藥報;2003年

8 新言;中醫(yī)證的本質(zhì)是細(xì)胞因子嗎？[N];科技日報;2005年

9 王蘇平;探究中醫(yī)證本質(zhì)[N];健康報;2004年

10 清華;世界多肽藥物的研發(fā)概況[N];中藥報;2001年

相關(guān)博士學(xué)位論文 前10條

1 李海軍;白細(xì)胞介素-21在乙型肝炎病毒感染中的作用研究[D];第三軍醫(yī)大學(xué);2015年

2 王婧瑤;卵巢癌患者髓源性抑制細(xì)胞、調(diào)節(jié)性T細(xì)胞及其相關(guān)細(xì)胞因子的表達(dá)及臨床意義[D];天津醫(yī)科大學(xué);2015年

3 徐金成;環(huán)意大利公路自行車賽中能量代謝與肌損傷及細(xì)胞因子相關(guān)變化[D];北京體育大學(xué);2015年

4 關(guān)連越;胰蛋白酶抑制劑保護(hù)肝缺血/再灌注損傷（HIRI）的機(jī)制和影響肝移植物存活的實驗研究[D];吉林大學(xué);2016年

5 王佳;抑制性細(xì)胞因子IL-35對急性髓細(xì)胞白血病免疫功能的影響及其機(jī)制研究[D];安徽醫(yī)科大學(xué);2016年

6 楊彬珧;血漿細(xì)胞因子與心率變異性和急性冠脈綜合征發(fā)病風(fēng)險的關(guān)聯(lián)性研究[D];華中科技大學(xué);2014年

7 石一寧;增生性玻璃體視網(wǎng)膜病變中炎前細(xì)胞因子的研究[D];第四軍醫(yī)大學(xué);1998年

8 牛忠英;三種細(xì)胞因子對牙周膜纖維細(xì)胞功能和基因調(diào)節(jié)作用的研究[D];第四軍醫(yī)大學(xué);1991年

9 夏紅天;細(xì)胞因子與肝癌血管內(nèi)皮細(xì)胞生長的臨床研究[D];中國人民解放軍軍醫(yī)進(jìn)修學(xué)院;2006年

10 陳力航;IL-18,IL-33對Th1,Th2細(xì)胞因子的表達(dá)調(diào)控在原發(fā)免疫性血小板減少癥發(fā)病中的作用[D];復(fù)旦大學(xué);2013年

相關(guān)碩士學(xué)位論文 前10條

1 鐘樹玉;復(fù)方補(bǔ)筋片對絕經(jīng)后膝骨關(guān)節(jié)炎血漿中性激素與細(xì)胞因子的影響[D];福建中醫(yī)藥大學(xué);2015年

2 高雁怩;ALV-J感染后細(xì)胞因子變化規(guī)律及其促進(jìn)IL-6產(chǎn)生的機(jī)制與效應(yīng)研究[D];中國農(nóng)業(yè)科學(xué)院;2015年

3 陳姣;原發(fā)免疫性血小板減少癥負(fù)調(diào)控分子PD-1和CTLA-4表達(dá)研究[D];蘭州大學(xué);2015年

4 黃瓊;改良細(xì)胞因子雞尾酒誘導(dǎo)肺腺癌細(xì)胞總RNA轉(zhuǎn)染樹突狀細(xì)胞疫苗抗腫瘤效應(yīng)的體內(nèi)研究[D];安徽醫(yī)科大學(xué);2015年

5 于炳旗;惡性腫瘤精神創(chuàng)傷后應(yīng)激障礙患者的發(fā)病特點及血清炎性因子水平的研究[D];河北大學(xué);2015年

6 牛小慧;雙氫青蒿素聯(lián)合順鉑對荷瘤大鼠細(xì)胞因子的影響[D];山西醫(yī)科大學(xué);2015年

7 孫聰聰;骨髓增殖性腫瘤中JAK2V617F突變及IL-6、TNF-α、IL-32、IL-37的定量測定及相關(guān)性研究[D];山東大學(xué);2015年

8 李少慧;乳酸桿菌對細(xì)胞因子及TLR-NF-κB途徑的調(diào)節(jié)作用研究[D];哈爾濱工業(yè)大學(xué);2015年

9 董杰;多肽及γ鏈細(xì)胞因子對慢性HBV感染者CD8~+T細(xì)胞上Tim-3的表達(dá)影響[D];第四軍醫(yī)大學(xué);2015年

10 李健;不同類型紅斑狼瘡患者血清中細(xì)胞因子的表達(dá)模式及意義[D];第三軍醫(yī)大學(xué);2015年

，

本文編號：2143093